人民卫生出版社

主编：邓春华 副主编：商学军、周辉良、孙祥宙、林浩成、吕伯东 编委：戴玉田、邓春华、高冰、黄燕平　、姜辉、姜涛、李付彪、梁季鸿、林浩成、吕伯东、商学军、孙祥宙、张炎、赵善超、周辉良<

1　概念、流行病学、危险因素、病因及病理生理

1.1　概念及流行病学

阴茎勃起（Erection）是一个由神经、内分泌、血管和阴茎海绵体组织精密调节、协调完成的复杂生理现象，包括阴茎动脉的充盈、小梁平滑肌的舒张、海绵体静脉闭塞等机制[1]，精神、心理因素在勃起过程中也起重要作用。

阴茎勃起功能障碍（Erectile dysfunction，ED）是指男性不能持续获得和维持足够的阴茎勃起以完成满意的性生活[1，2]。ED是男性最常见的性功能障碍之一，是一种影响身心健康的慢性疾病，不仅影响患者及其伴侣的生活质量[3]，也可能

1.Gratzke C， Angulo J， Chitaley K， et al.Anatomy， physiology， and pathophysiology of erectile dysfunction.J Sex Med 2010； 7： 445-75.

2.K.Hatzimouratidis FG， I.Moncada， et al.Guidelines on Male Sexual Dysfunction： Erectile dysfunction and premature ejaculation.European Association of Urology 2016.

3.FisherWA， Eardley I， McCabe M， Sand M.Erectile dysfunction（ED） is a shared sexual concern of couples I： couple conceptions of ED.JSex Med 2009； 6： 2746-60.

4.Gandaglia G， Briganti A， Jackson G， etal.A systematic review of theassociation between erectile dysfunction and cardiovascular disease.Eur Urol 2014； 65： 968-78.

5.Feldman HA， Goldstein I， Hatzichristou DG， Krane RJ， McKinlay JB.Impotence and itsmedical and psychosocial correlates： results of the Massachusetts Male Aging Study.JUrol 1994； 151： 54-61.

6.Johannes CB， Araujo AB， Feldman HA， Derby CA， Kleinman KP， McKinlay JB.Incidence of erectile dysfunction inmen 40 to 69 years old： longitudinal results from the Massachusettsmale aging study.JUrol 2000；163：460-3.

7.张庆江，朱积川，许清泉，姜辉.三城市2226例男性勃起功能流行病学调查.中国男科学杂志2003： 191-193.

8.樊云井，李欣迎，陶国振，董云玲，樊兆宜.山东省3991例男性勃起功能流行病学调查.中国性科学2012：3-5.

9.张志超，孙斌，刘永胜，陈琦，辛钟成，郭应禄.北京市社区已婚男子勃起功能障碍患病情况调查.中华泌尿外科杂志2003：63-65.

10.许振付，张朝红，刘曼丽等.佛山市顺德区流动人口成年男性生殖健康状况调查.中国男科学杂志2013：35-38.

11.邓天勤，谢雨莉，阮建波等.东莞市1812名流动男性勃起功能障碍流行病学调查.中国男科学杂志2015：31-34.

12.刘德风，姜辉，洪锴，赵连明，马潞林，朱积川.近5年来中国11个城市门诊勃起功能障碍患者的流行病学变化.中华男科学杂志2009：724-6.

13.Hall SA， Shackelton R， Rosen RC， Araujo AB.Risk factors for incidenterectile dysfunction among community-dwellingmen.JSex Med 2010； 7： 712-22.

14.Jackson G， Montorsi P， Adams MA， et al.Cardiovascular aspects of sexualmedicine.JSex Med 2010； 7：1608-26.

15.Lee JC， Benard F， Carrier S， Talwar V， Defoy I.Domen withmild erectile dysfunction have the same risk factors as the general erectile dysfunction clinical trial population？ BJU Int 2011； 107： 956-60.

16.Hackett G， Krychman M， Baldwin D， et al.Coronary Heart Disease， Diabetes， and Sexuality in Men.J Sex Med 2016； 13： 887-904.

17.Seftel AD， de la Rosette J， Birt J， Porter V， Zarotsky V， Viktrup L.Coexisting lower urinary tract symptoms and erectile dysfunction： a systematic review of epidemiological data.Int JClin Pract 2013； 67：32-45.

18.Rosen R， Altwein J， Boyle P， et al.Lower urinary tract symptoms and male sexual dysfunction： themultinational survey of the agingmale （MSAM-7）.Eur Urol 2003； 44： 637-649.

19.宋健，邵强，田野等.北京社区中老年男性下尿路症状和勃起功能障碍的相关性调查.中华医学杂志2011； 91： 2706-9.

20.Davis-Joseph B， Tiefer L， Melman A.Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction.Urology 1995； 45： 498-502.

21.Hatzichristou D，Hatzimouratidis K，Bekas M，Apostolidis A，Tzortzis V，Yannakoyorgos K.Diagnostic steps in the evaluation of patients with erectile dysfunction.JUrol 2002； 168： 615-20.

22.Hatzimouratidis K， Amar E， Eardley I， et al.Guidelines on male sexual dysfunction： erectile dysfunction and premature ejaculation.Eur Urol 2010； 57： 804-14.

23.Rosen RC， Riley A， Wagner G， Osterloh IH， Kirkpatrick J， Mishra A.The international index of erectile function （IIEF）： amultidimensional scale for assessment of erectile dysfunction.Urology 1997； 49： 822-30.

24.朱积川.男子勃起功能障碍诊治指南.中国男科学杂志2004；18：68-72.

25.Gandaglia G， Briganti A，Jackson G， et al.A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease.Eur Urol 2013； 23： 851-858.

26.Jackson G， Rosen RC， K loner RA， Kostis JB.The second Princeton consensus on sexual dysfunction and cardiac risk： new guidelines for sexualmedicine.JSex Med 2006； 3： 28-36.

27.Laumann EO， Paik A，Rosen RC.The epidemiology of erectile dysfunction：results from the National Health and Social Life Survey.Int J Impot Res 1999； 11： 60-64.

28.Capogrosso P， Colicchia M， Ventimiglia E，et al.One patient out of fourwith newly diagnosed erectile dysfunction is a youngman-worrisome picture from the everyday clinical practice.JSex Med 2013； 10： 1833-41.

29.MMPI全国协作组.明尼苏达多相个性测查表使用指导书.北京1989；41.

30.Tondo L， Cantone M， Carta M， Laddomada A， Mosticoni R， Rudas N.An MMPIevaluation ofmale sexual dysfunction.JClin Psychol 1991； 47： 391-6.

31.童辉杰.SCL-90量表及其常模20年变迁之研究.心理科学2010：928-30.

32.Schmitz N， Hartkamp N， Kiuse J， Franke GH， Reister G， TressW.The Symptom Check-List-90-R （SCL-90-R）： a German validation study.Qual Life Res 2000； 9： 185-93.

33.Buvat J， MaggiM， Gooren L， et al.Endocrine aspects ofmale sexual dysfunctions.JSex Med 2010； 7：1627-56.

34.Bhasin S， Cunningham GR， Hayes FJ， et al.Testosterone therapy in men with androgen deficiency syndromes： an Endocrine Society clinical practice guideline.JClin EndocrinolMetab 2010； 95： 2536-59.

35.Isidori AM， Buvat J， Corona G， etal.A critical analysis of the role of testosterone in erectile function： from pathophysiology to treatment-a systematic review.Eur Urol 2014； 65： 99-112.

36.O′Connor DB， Lee DM， Corona G， et al.The relationships between sex hormones and sexual function in middle-aged and older Europeanmen.JClin Endocrinol Metab 2011； 96： 2010-216.

37.MaggiM， Buvat J， Corona G， Guay A， Torres LO.Hormonal causes ofmale sexual dysfunctions and their management（hyperprolactinemia， thyroid disorders， GH disorders， and DHEA）.J Sex Med 2013； 10：661-77.

38.Heidenreich A， Bastian PJ， Bellmunt J， et al.EAU guidelines on prostate cancer.part1： screening， diagnosis， and local treatmentwith curative intent-update 2013.Eur Urol 2014； 65： 124-37.

39.Ghanem HM，Salonia A， Martin-Morales A.SOP： physical examination and laboratory testing for men with erectile dysfunction.JSex Med 2013； 10： 108-10.

40.El-Sakka AI.What is the current role of intracavernosal injection inmanagement of erectile dysfunction？Int J Impot Res 2016； 28： 88-95.

41.Sikka SC， Hellstrom WJ， Brock G， Morales AM.Standardization of vascular assessment of erectile dysfunction： standard operating procedures for duplex ultrasound.JSex Med 2013； 10： 120-9.

42.Corona G， Fagioli G， Mannucci E， et al.Penile doppler ultrasound in patients with erectile dysfunction（ED）： role of peak systolic velocitymeasured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease.JSex Med 2008； 5： 2623-34.

43.Deanfield JE， Halcox JP， Rabelink TJ.Endothelial function and dysfunction： testing and clinical relevance. Circulation 2007； 115： 1285-95.

44.Costa C， Virag R.The endothelial-erectile dysfunction connection： an essential update.JSex Med 2009； 6：2390-404.

45.Virag R， Floresco J， Richard C.Impairment of shear-stress-mediated vasodilation of cavernous arteries in erectile dysfunction.Int J Impot Res 2004； 16： 39-42.

46.Axtell AL， Gomari FA， Cooke JP.Assessing endothelial vasodilator function with the Endo-PAT 2000. Journal of visualized experiments：JoVE 2010.

47.Jedlickova L， Merkovska L， Jackova L， et al.Effect of Ivabradine on Endothelial Function in Patients with Stable Angina Pectoris： Assessment with the Endo-PAT 2000 Device.Advances in therapy 2015； 32：962-70.

48.Pelliccione F， D′Angeli A， Filipponi S， etal.Serum from patientswith erectile dysfunction inhibits circulating angiogenic cells from healthy men： relationship with cardiovascular risk， endothelial damage and circulating angiogenicmodulators.International journal of andrology 2012； 35： 645-52.

49.El Melegy NT， Ali ME， Awad EM.Plasma levels of endothelin-1， angiotensin II， nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction.BJU Int 2005； 96：1079-86.

50.Baumhakel M，Werner N，Bohm M，Nickenig G.Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease.Eur Heart J 2006； 27： 2184-8.

51.Foresta C， Caretta N， Lana A， Cabrelle A， Palu G， Ferlin A.Circulating endothelial progenitor cells in subjects with erectile dysfunction.Int J Impot Res 2005； 17： 288-90.

52.Lee JW， Park HJ， Park NC.Serum High-Sensitivity C-Reactive Protein Levels and Response to 5mg Tadalafil Once Daily in PatientsWith Erectile Dysfunction and Diabetes.Korean JUrol 2013； 54： 858-64.

53.Yao F， Liu L， Zhang Y， etal.Erectile dysfunctionmay be the first clinical sign of insulin resistance and endothelial dysfunction in youngmen.Clinical research in cardiology：official journal of the German Cardiac Society 2013； 102： 645-51.

54.Ertekin C， AkyurekliO， Gurses AN， Turgut H.The value of somatosensory-evoked potentials and bulbocavernosus reflex in patientswith impotence.Acta neurologica Scandinavica 1985； 71： 48-53.

55.Opsomer RJ， Guerit JM， Wese FX， Van Cangh PJ.Pudendal cortical somatosensory evoked potentials.The Journal of urology 1986； 135： 1216-8.

56.Giuliano F，Rowland DL.Standard operating procedures for neurophysiologic assessment ofmale sexual dysfunction.The journal of sexualmedicine 2013； 10： 1205-11.

57.Hatzichristou D，Rosen RC， Broderick G，et al.Clinical evaluation and management strategy for sexual dysfunction inmen and women.JSex Med 2004； 1： 49-57.

58.Chan SS， Leung DY， Abdullah AS， etal.Smoking-cessation and adherence intervention among Chinese patientswith erectile dysfunction.Am JPrev Med 2010； 39： 251-8.

59.Harte CB， Meston CM.Association between smoking cessation and sexual health in men.BJU Int 2012；109：888-96.

60.Cheng JY， Ng EM， Ko JS， Chen　RY.Physical activity and　erectile dysfunction： meta-analysis of population-based studies.Int J Impot Res 2007； 19： 245-52.

61.Kratzik CW， Lackner JE， Mark I， et al.How much physical activity is needed tomaintain erectile function？Results of the Androx Vienna Municipality Study.Eur Urol 2009； 55： 509-16.

62.Koskimaki J， Shiri R， Tammela T， Hakkinen J， Hakama M， Auvinen A.Regular intercourse protects against erectile dysfunction： Tampere Aging Male Urologic Study.Am JMed 2008； 121： 592-6.

63.Ma Y， Qin H.Regular and frequent sexual intercourse for elderlymen could preserve erectile function： Med Hypotheses.2009Mar； 72 （3）： 370.doi： 10.1016/j.mehy.2008.10.001.Epub 2008 Nov 8.

64.郭应禄，朱积川，潘天明等.口服西地那非治疗勃起功能障碍疗效和安全性的临床研究.中华泌尿外科杂志 2001；22：389-94.

65.Meldrum DR， Gambone JC， Morris MA， Meldrum DA， Esposito K， Ignarro LJ.The link between erectile and cardiovascular health： the canary in the coalmine.Am JCardiol 2011； 108： 599-606.

66.Ramirez R，Pedro-Botet J，Garcia M，et al.Erectile dysfunction and cardiovascular risk factors in a Mediterranean diet cohort.Intern Med J 2016； 46： 52-6.

67.Taylor J.Mediterranean diet linked to improved cardiovascular function in erectile dysfunction patients.Eur Heart J 2015； 36： 836.

68.Esposito K， Giugliano F， Maiorino MI， Giugliano D.Dietary factors， Mediterranean diet and erectile dysfunction.JSex Med 2010； 7： 2338-45.

69.Giugliano D， Giugliano F， Esposito K.Sexual dysfunction and the Mediterranean diet.Public Health Nutr 2006； 9： 1118-20.

70.Babaev A，Jhaveri RR.Angiography and endovascular revascularization of pudendal artery atherosclerotic disease in patientswithmedically refractory erectile dysfunction.J Invasive Cardiol 2012； 24： 236-40.

71.Esposito K，Giugliano D.Lifestyle/dietary recommendations for erectile dysfunction and female sexual dysfunction.Urol Clin North Am 2011； 38： 293-301.

72.Burnett AL.Erectile dysfunction management for the future.JAndrol 2009； 30： 391-6.

73.王东伟，史桂霞，夏小明.高血压及抗高血压药物对勃起功能的影响与研究进展.心血管病学进展2006； 27： 592-5.

74.Grover SA， Lowensteyn I， Kaouache M， et al.The prevalence of erectile dysfunction in the primary care setting： importance of risk factors for diabetes and vascular disease.Arch Intern Med 2006； 166： 213-9.

75.Derby CA， Mohr BA， Goldstein I， Feldman HA， Johannes CB， McKinlay JB.Modifiable risk factorsand erectile dysfunction： can lifestyle changesmodify risk？ Urology 2000； 56： 302-6.

76.Bacon CG， Mittleman MA， Kawachi I， Giovannucci E， Glasser DB， Rimm EB.Sexual function in men older than 50 years of age： results from the health professionals follow-up study.Ann Intern Med 2003； 139：161-8.

77.Jackson G， Boon N， Eardley I， et al.Erectile dysfunction and coronary artery disease prediction： evidencebased guidance and consensus.Int JClin Pract 2010； 64： 848-57.

78.A l-Hunayan A， Al-Mutar M， Kehinde EO， Thalib L， Al-Ghorory M.The prevalence and predictors of erectile dysfunction inmen with newly diagnosed with type 2 diabetesmellitus.BJU Int2007； 99： 130-4.

79.Aversa A， Bruzziches R， Vitale C， et al.Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 2007； 3： 451-64.

80.Valiquette L， MontorsiF， Auerbach S.First-dose successwith vardenafil inmen with erectile dysfunction and associated comorbidities： RELY-I.Int JClin Pract 2006； 60： 1378-85.

81.Greenstein A， Mabjeesh NJ， Sofer M， Kaver I， Matzkin H， Chen J.Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed？ JUrol 2005； 173： 530-2.

82.Corona G，Lee DM，Forti G，et al.Age-Related Changes in General and Sexual Health in Middle-Aged and Older Men： Results from the European Male Ageing Study （EMAS）.The Journal of Sexual Medicine 2010；7：1362-80.

83.Hall SA， Shackelton R， Rosen RC， Araujo AB.Sexual activity， erectile dysfunction， and incident cardiovascular events.Am JCardiol 2010； 105： 192-7.

84.Tom　F.Lue M， ScD　（Hon）， FACS.Physiology of penile erection and pathophysiology of erectile dysfunction.In： Campbell-walsh urology 10th； 2011： 688-720.

85.Goldstein I， Lue TF， Padma-Nathan H， Rosen RC， Steers WD， Wicker PA.Oral sildenafil in the treatment of erectile dysfunction.Sildenafil Study Group.N Engl JMed 1998； 338： 1397-404.

86.Curran M， Keating G.Tadalafil.Drugs 2003； 63： 2203-12.

87.Keating GM， Scott LJ.Vardenafil： a review of its use in erectile dysfunction.Drugs 2003； 63： 2673-703.

88.Sanford M.Vardenafil orodispersible tablet.Drugs 2012； 72： 87-98.

89.Tsertsvadze A， Fink HA， Yazdi F， et al.Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction： a systematic review and meta-analysis.Ann Intern Med 2009； 151： 650-61.

90.Porst H， GacciM， Buttner H， Henneges C， Boess F.Tadalafil once daily inmen with erectile dysfunction：an integrated analysis of data obtained from 1913 patients from six randomized， double-blind， placebo-controlled， clinical studies.Eur Urol 2014； 65： 455-64.

91.GacciM，Andersson KE，Chapple C，et al.Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.Eur Urol 2016； 70： 124-33.

92.Mathers MJ， Klotz T， Brandt AS， Roth S， Sommer F.Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence.BJU Int 2008；101：1129-34.

93.Vardi Y， Appel B， Ofer Y， Greunwald I， Dayan L， Jacob G.Effect of chronic sildenafil treatment on penile endothelial function： a randomized， double-blind， placebo controlled study.JUrol 2009； 182： 2850-5.

94.BurnettAL， Strong TD， Trock BJ， Jin L， Bivalacqua TJ， Musicki B.Serum biomarkermeasurementsof endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabeticmen with erectile dysfunction.JUrol 2009； 181： 245-51.

95.Rosano GM， Aversa A，Vitale C， Fabbri A， FiniM，Spera G.Chronic treatmentwith tadalafil improves endothelial function inmen with increased cardiovascular risk.Eur Urol 2005； 47： 214-20.

96.Santi D， Granata AR，Guidi A， et al.Six months of daily treatmentwith vardenafil improves parameters of endothelial inflammation and of hypogonadism inmale patientswith type 2 diabetes and erectile dysfunction：a randomized， double-blind， prospective trial.Eur JEndocrinol 2016； 174： 513-22.

97.Behr-Roussel D，Gorny D，Mevel K，etal.Chronic sildenafil improveserectile function and endothelium-dependent cavernosal relaxations in rats： lack of tachyphylaxis.Eur Urol 2005； 47： 87-91.

98.Ferrini MG， Davila HH， Kovanecz I， Sanchez SP， Gonzalez-Cadavid NF， Rajfer J.Vardenafil prevents fibrosis and loss of corporal smoothmuscle thatoccurs after bilateral cavernosal nerve resection in the rat.Urology 2006； 68： 429-35.

99.Ferrini MG， Kovanecz I， Sanchez S， et al.Long-term continuous treatmentwith sildenafil ameliorates agingrelated erectile dysfunction and the underlying corporal fibrosis in the rat.Biol Reprod 2007； 76： 915-23.

100.Kovanecz I， Rambhatla A， Ferrini MG， et al.Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection.BJU Int2008； 101： 203-10.

101.Vignozzi L， Filippi S， Morelli A， et al.Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat.JSex Med 2006； 3： 419-31.

102.Liu G，Sun X，Dai Y，et al.Chronic administration of sildenafilmodified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction.JSex Med 2010； 7： 3868-78.

103.Schwartz BG， Jackson G， Stecher VJ， Campoli-Richards DM， Kloner RA.Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions.Am JMed 2013； 126： 192-9.

104.Chen L， Staubli SE， Schneider MP， et al.Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction： a trade-off network meta-analysis.Eur Urol 2015； 68： 674-80.

105.Mirone V， Costa P， Damber JE， et al.An evaluation of an alternative dosing regimen with tadalafil， 3 times/week， formen with erectile dysfunction： SURE study in 14 European countries.Eur Urol 2005； 47：846-54.

106.K loner RA.Novel phosphodiesterase type 5 inhibitors：assessing hemodynamic effects and safety parameters. Clin Cardiol 2004； 27： 120-5.

107.ThadaniU， Smith W， Nash S， et al.The effectof vardenafil， a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction，on the cardiovascular response to exercise in patients with coronary artery disease.JAm Coll Cardiol 2002； 40： 2006-12.

108.Vardi Y， Bulus M， Reisner S， et al.Effects of sildenafil citrate（Viagra） on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patientswith erectile dysfunction and cardiovascular disease.Eur Urol 2003； 43： 544-51.

109.Auerbach SM，Gittelman M，Mazzu A，Cihon F，Sundaresan P，White WB.Simultaneous administration of vardenafil and tamsulosin does not induce clinically significanthypotension in patientswith benign prostatic hyperplasia.Urology 2004； 64： 998-1003.

110.Hatzichristou　D.Phosphodiesterase 5　inhibitors and　nonarteritic　anterior ischem ic optic　neuropathy（NAION）： coincidence or causality？ JSex Med 2005； 2： 751-8.

111.Purvis K， Muirhead GJ， Harness JA.The effects of sildenafil on human sperm function in healthy volunteers.Br JClin Pharmacol 2002； 53： 53-60.

112.Hellstrom WJ， Gittelman M， Jarow J， et al.An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg： results of amulticenter， randomized， double-blind， placebocontrolled， 9-month study.Eur Urol 2008； 53： 1058-65.

113.Jarvi K， Dula E， Drehobl M， Pryor J， Shapiro J， Seger M.Daily vardenafil for 6months has no detrimental effects on semen characteristics or reproductive hormones inmen with normal baseline levels.JUrol2008；179：1060-5.

114.Park NC， Kim TN， Park HJ.Treatment Strategy for Non-Responders to PDE5 Inhibitors.World JMens Health 2013； 31： 31-5.

115.Suetomi T， Kawai K， Hinotsu S， et al.Negative impact ofmetabolic syndrome on the responsiveness to sildenafil in Japanesemen.JSex Med 2008； 5： 1443-50.

116.Hatzichristou D， Moysidis K， Apostolidis A， et al.Sildenafil failuresmay be due to inadequate patient instructions and follow-up： a study on 100 non-responders.Eur Urol 2005； 47： 518-22.

117.Rajagopalan P， Mazzu A， Xia C， Dawkins R， Sundaresan P.Effect of high-fat breakfast and moderate-fat eveningmeal on the pharmacokinetics of vardenafil，an oral phosphodiesterase-5 inhibitor for the treatmentof erectile dysfunction.JClin Pharmacol 2003； 43： 260-7.

118.Nichols DJ， Muirhead GJ， Harness JA.Pharmacokinetics of sildenafil after single oral doses in healthy male subjects： absolute bioavailability， food effects and dose proportionality.Br J Clin Pharmacol 2002； 53：5-12.

119.Rosen RC，Padma-Nathan H， Shabsigh R，Saikali K， Watkins V，Pullman W.Determ ining the earliest time within 30 m inutes to erectogenic effect after tadalafil 10 and 20 mg： a multicenter， randomized，double-blind， placebo-controlled， at-home study.JSex Med 2004； 1： 193-200.

120.Padma-Nathan H， Stecher VJ， Sweeney M， Orazem J， Tseng LJ， DeriesthalH.Minimal time to successful intercourse after sildenafil citrate： results of a randomized， double-blind， placebo-controlled trial.Urology 2003； 62： 400-3.

121.Hatzimouratidis K，Moysidis K，Bekos A， Tsimtsiou Z， Ioannidis E， Hatzichristou D.Treatment strategy for “non-responders” to tadalafil and vardenafil： a real-life study.Eur Urol 2006； 50： 126-32.

122.Dadkhah F， Safarinejad MR，AsgariMA，Hosseini SY，Lashay A， Amini E.Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010； 22： 51-60.

123.Gokkaya SC， Ozden C， Levent Ozdal O， Hakan Koyuncu H， Guzel O， Memis A.Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction.Scand JUrol Nephrol 2008； 42： 437-40.

124.Shabsigh R，Kaufman JM，Steidle C，Padma-Nathan H.Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone.J Urol 2004； 172： 658-63.

125.王进，李森，张友朋等.PDE5i治疗无效的青壮年ED患者的临床治疗对策 （附100例报告）.临床泌尿外科杂志2016：331-5.

126.Malavige LS， Levy JC.Erectile dysfunction in diabetesmellitus.JSex Med 2009； 6： 1232-47.

127.Foresta C， Caretta N， Rossato M， Garolla A， Ferlin A.Role of androgens in erectile function.J Urol 2004； 171： 2358-62.

128.Saad F， Gooren LJ， Haider A， Yassin A.A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.J Androl 2008； 29： 102-5.

129.Mannikarottu AS， Hypolite JA， Zderic SA， Wein AJ， Chacko S， Disanto ME.Regional alterations in the expression of smooth musclemyosin isoforms in response to partial bladder outlet obstruction.JUrol 2005；173：302-8.

130.Corona G， Petrone L， Fisher AD， et al.Six-month adm inistration of 1%testosterone gel is able to restore erectile function in hypogonadal patientswith erectile dysfunction.Arch Ital Urol Androl 2008； 80： 103-8.

131.Yassin AA，Saad F.Dramatic improvementof penile venous leakage upon testosterone administration.A case report and review of literature.Andrologia 2006； 38： 34-7.

132.Aliaev Iu G， Vinarov AZ，Akhvlediani ND.[Choice of treatment of erectile dysfunction associated with hypogonadism].Urologiia 2010； 4： 37-8.

133.Mohee A， Bretsztajn L， Eardley I.The evaluation of apomorphine for the treatment of erectile dysfunction. Expert Opin Drug Metab Toxicol 2012； 8： 1447-53.

134.Riley A，Main M，Morgan F.Inhalation device allows novel administration of apomorphine inmen with erectile dysfunction-efficacy and safety findings.JSex Med 2010； 7： 1508-17.

135.Lebret T， Herve JM， Gorny P， Worcel M， Botto H.Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride：a new oral therapy for erectile dysfunction.Eur Urol 2002； 41： 608-13.

136.Fink HA， MacDonald R， Rutks IR， Wilt TJ.Trazodone for erectile dysfunction： a systematic review and meta-analysis.BJU Int 2003； 92： 441-6.

137.Taneja R.A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone： a pilot study.JSex Med 2007； 4： 1136-41.

138.Yuan J， Hoang AN，Romero CA，Lin H，Dai Y， Wang R.Vacuum therapy in erectile dysfunction-science and clinical evidence.Int J Impot Res 2010； 22： 211-9.

139.胡礼泉，张新华.勃起功能障碍.郭应禄，胡礼泉主编 男科学 北京：人民卫生出版社 2004：699-701.

140.林浩成，Wang G，Wang R.真空勃起装置在前列腺癌根治术后阴茎康复治疗中的应用.中华男科学杂志 2015；21：195-9.

141.辛钟成.勃起功能障碍的诊断.辛钟成，郭应禄主编勃起功能障碍的外科治疗学.北京：北京医科大学出版社2000：229-33.

142.Raina R， Pahlajani G， Agarwal A， Jones S， Zippe C.Long-term potency after early use of a vacuum erection device following radical prostatectomy.BJU Int 2010； 106： 1719-22.

143.Canguven O， Bailen J， Fredriksson W， Bock D， Burnett AL.Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction.J Sex Med 2009； 6： 2561-7.

144.Vardi Y， Appel B， Jacob G， Massarwi O， Gruenwald I.Can low-intensity extracorporeal shockwave therapy improve erectile function？A　6-month follow-up pilot study in patients with organic erectile dysfunction.Eur Urol 2010； 58： 243-8.

145.Vardi Y， Appel B， Kilchevsky A， Gruenwald I.Does low intensity extracorporeal shock wave therapy have a physiological effecton erectile function？ Short-term results of a randomized， double-blind， sham controlled study.JUrol 2012； 187： 1769-75.

146.Rosen RC， Allen KR， Ni X， Araujo AB.Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale.European urology.Nov 2011； 60 （5）：1010-1016.

147.Kitrey， ND.， Gruenwald I， Appel B， et al.Penile low-intensity shockwave treatment is able to shift PDE5i non-responders to responders： A double-blind sham-controlled study.J Urol.2016， May； 195 （5）：1550-5.

148.Gruenwald， IB.Appel， and Y.Vardi.Low-intensity extracorporeal shock wave therapy-a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy.J Sex Med.2012 Jan； 9 （1）： 259-64.

149.Coombs PG， Heck M， Guhring P， Narus J， Mulhall JP.A review of outcomes of an intracavernosal injection therapy programme.BJU Int 2012； 110： 1787-91.

150.Eardley I， Donatucci C， Corbin J， et al.Pharmacotherapy for erectile dysfunction.J Sex Med 2010； 7：524-40.

151.Virag R.Intracavernous injection of papaverine for erectile failure： Lancet.1982 Oct23； 2 （8304）： 938.

152.IIALB.Evaluation and Management of Erectile Dysfunction.Campbell-Walsh Urology 11th Philadelphia：Elsevier 2016：643-65.

153.Szasz G， Stevenson RW， Lee L， Sanders HD.Induction of penile erection by intracavernosal injection： a double-blind comparison of phenoxybenzamine versus papaverine-phentolamine versus saline.Arch Sex Behav 1987； 16： 371-8.

154.Bechara A，Casabe A， Cheliz G，Romano S， Rey H， Fredotovich N.Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.JUrol 1997； 157： 2132-4.

155.Padma-Nathan H， Hellstrom WJ， Kaiser FE， et al.Treatment ofmen with erectile dysfunction with transurethral alprostadil.Medicated Urethral System for Erection （MUSE） Study Group.N Engl JMed 1997；336：1-7.

156.Montague DK， Jarow JP， Broderick GA， et al.Chapter 1： The management of erectile dysfunction： an AUA update.JUrol 2005； 174： 230-9.

157.Wayne JG Hellstrom DKm.Sexual Medicine-Sexual dysfunctions in men and women.In F.Montorsi，R. Basson， G.Adaikan， E.Becher， A.Clayton， F.Giuliano， S.Khoury， I.Sharlip ed， 3nd International Consultation on Sexual Dysfunctions.Chapt18.Paris 2010：910-2.

158.Zhang B， Chen J， Xiao H， et al.Treatment of penile deep dorsal venous leakage of erectile dysfunction by embedding the deep dorsal vein of the penis： a single center experience with 17 patients.JSex Med 2009；6：1467-73.

159.Siddiqi K， Lewis RW.Surgical therapy for the treatment of erectile dysfunction.Nat Clin Pract Urol 2008；5：174-5.

160.Sohn M， Hatzinger M， Goldstein I， Krishnamurti S.Standard operating procedures for vascular surgery in erectile dysfunction： revascularization and venous procedures.JSex Med 2013； 10： 172-9.

161.Ang LP， Lim PH.Penile revascularisation for vascular impotence.Singapore Med J 1997； 38： 285-8.

162.DePalma RG，Olding M， Yu GW，et al.Vascular interventions for impotence： lessons learned.J Vasc Surg 1995； 21： 576-84.

163.Grasso M，Lania C，CastelliM，Deiana G，Francesca F，Rigatti P.Deep dorsal vein arterialization in vasculogenic impotence： our experience.Arch Ital Urol Nefrol Androl 1992； 64： 309-12.

164.Jarow JP，DeFranzo AJ.Long-term results of arterial bypass surgery for impotence secondary to segmental vascular disease.JUrol 1996； 156： 982-5.

165.Montorsi F， Deho F， Salonia A， etal.Penile implants in the era of oral drug treatment for erectile dysfunction.BJU Int 2004； 94： 745-51.

166.W ilson SK， Carson CC， Cleves MA，Delk JR，2nd.Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin.JUrol 1998； 159： 1537-9.

167.Bishop JR， Moul JW， Sihelnik SA， Peppas DS， Gorm ley TS， McLeod DG.Use ofglycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections.JUrol 1992； 147： 386-8.

168.Montague DK， Angermeier KW.Penile prosthesis implantation.Urol Clin North Am 2001； 28： 355-61.

169.Martinez DR， TerleckiR， BrantWO.The Evolution and Utility of the Small-Carrion Prosthesis， Its Impact，and Progression to the Modern-Day Malleable Penile Prosthesis.JSex Med 2015； 7： 423-30.

170.Hakky T， Lentz A， Sadeghi-Nejad H， Khera M.The Evolution of the Inflatable Penile Prosthesis Reservoir and Surgical Placement.JSex Med 2015； 7： 464-7.

171.Carson CC，3rd.Efficacy of antibiotic impregnation of inflatable penile prostheses in decreasing infection in original implants.JUrol 2004； 171： 1611-4.

172.Wolter CE， Hellstrom WJ.The hydrophilic-coated inflatable penile prosthesis： 1-year experience.J Sex Med 2004； 1： 221-4.

173.D′Amico DF， Parimbelli P， Ruffolo C.Antibiotic prophylaxis in clean surgery： breast surgery and hernia repair.JChemother 2001：108-11.

174.ZibariGB，Gadallah MF，Landreneau M，et al.Preoperative vancomycin prophylaxis decreases incidence of postoperative hemodialysis vascular access infections.Am JKidney Dis 1997； 30： 343-8.

175.Hill C，Flamant R，Mazas F，Evrard J.Prophylactic cefazolin versus placebo in total hip replacement.Report of amulticentre double-blind randomised trial.Lancet 1981； 1： 795-6.

176.Montorsi F， Rigatti P， Carmignani G， et al.AMS three-piece inflatable implants for erectile dysfunction： a long-term multi-institutional study in 200 consecutive patients.Eur Urol 2000； 37： 50-5.

177.Goldstein I， Newman L， Baum N， et al.Safety and efficacy outcome of mentor alpha-1 inflatable penile prosthesis implantation for impotence treatment.JUrol 1997； 157： 833-9.

178.W ilson SK， Henry GD， Delk JR， Jr.， Cleves MA.The mentor Alpha 1 penile prosthesis with reservoir lock-out valve：effective prevention of auto-inflation with improved capability for ectopic reservoir placement. JUrol 2002； 168： 1475-8.

179.Thiel DD， Broderick GA，Bridges M.Utility ofmagnetic resonance imaging in evaluating inflatable penile prosthesismalfunction and complaints.Int J Impot Res 2003； 15： 155-61.

180.中华人民共和国国家标准中医临床诊疗术语.（疾病部分10.19）GB/T 16751.1-1997.

181.国家中医药管理局医政司104个病种中医诊疗方案.2012：202-4.

182.樊千，薛建国.阳痿中医分型证候标准量化研究.江苏中医药2010；42：28-9.

183.毕焕洲，赵永厚.阳痿中医诊治的循证医学研究.中国性科学2013；22：47-51.

184.秦国政.勃起功能障碍 （阳痿）中医发病学规律研究.云南中医学院学报2003；26：6-8.

185.Shenfeld OZ， Kiselgorf D， Gofrit ON， et al.The incidence and causes of erectile dysfunction after pelvic fractures associated with posterior urethral disruption.JUrol 2003； 169： 2173-6.

186.Sangkum P， Levy J， Yafi FA， Hellstrom WJ.Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients： diagnosis， treatment， and outcomes.Andrology 2015； 3： 443-9.

187.Shenfeld OZ， Gofrit ON， Gdor Y， Landau I， Katz R， Pode D.The role of sildenafil in the treatment of erectile dysfunction in patients with pelvic fracture urethral disruption.JUrol 2004； 172： 2350-2.

188.Fu Q， Sun X， Tang C， Cui R， Chen L.An assessmentof the efficacy and safety of sildenafil administered to patientswith erectile dysfunction referred for posterior urethroplasty：a single-center experience.JSex Med 2012； 9： 282-7.

189.彭靖，袁亦铭，张志超等.每日小剂量他达拉非治疗骨盆骨折尿道断裂后勃起功能障碍的疗效观察.中华男科学杂志 2013；19：443-5.

190.Engel JD.Effect on sexual function of a vacuum erection device post-prostatectomy.Can JUrol 2011； 18：5721-5.

191.CuiWS， Kim SD， Choi KS， Zhao C， Park JK.An unusual successwith simultaneous urethral repair and reimplantation of penile prosthesis in a patientwith urethral stricture induced by rotated tubing.J Sex Med 2009； 6： 1783-6.

192.Biering-Sorensen I， Hansen RB， Biering-Sorensen F.Sexual function in a traumatic spinal cord injured population 10-45 years after injury.JRehabilMed 2012； 44： 926-31.

193.Courtois F， Charvier K.Sexual dysfunction in patients with spinal cord lesions.Handb Clin Neurol 2015；130：225-45.

194.Hess MJ， Hough S.Impact of spinal cord injury on sexuality： broad-based clinical practice intervention and practical application.JSpinal Cord Med 2012； 35： 211-8.

195.Lombardi G， Musco S， Wyndaele JJ， Del Popolo G.Treatments for erectile dysfunction in spinal cord patients： alternatives to phosphodiesterase type 5 inhibitors？ A review study.Spinal Cord 2015； 53： 849-54.

196.Soler JM， Previnaire JG， Denys P， Chartier-Kastler E.Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.Spinal Cord 2007； 45： 169-73.

197.LombardiG，Nelli F，Celso M，MencariniM，Del Popolo G.Treating erectile dysfunction and central neurological diseaseswith oral phosphodiesterase type 5 inhibitors.Review of the literature.JSex Med 2012； 9： 970-85.

198.Chochina L， Naudet F， Bonan I， et al.Intracavernous injections in spinal cord injured men with erectile dysfunction， a systematic review and meta-analysis.Ann Phys Rehabil Med 2016； 10： 237.

199.Zermann DH， Kutzenberger J， Sauerwein D， Schubert J， Loeffler U.Penile prosthetic surgery in neurologically impaired patients： long-term followup.JUrol 2006； 175： 1041-4.

200.Burnett AL.Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy.Urology 2003； 61： 491-7.

201.Moreland RB.Is there a role of hypoxemia in penile fibrosis：a viewpoint presented to the Society for the Study of Impotence.Int J Impot Res 1998； 10： 113-20.

202.Mulhall JP， Slovick R， Hotaling J， et al.Erectile dysfunction after radical prostatectomy： hemodynamic profiles and their correlation with the recovery of erectile function.JUrol 2002； 167： 1371-5.

203.Mulhall JP，Graydon RJ.The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy.Int JImpot Res 1996； 8： 91-4.

204.Burnett AL.Current rehabilitation strategy：clinical evidence for erection recovery after radical prostatectomy. Transl Androl Urol 2013； 2： 24-31.

205.Zippe CD，Kedia AW，Kedia K，Nelson DR，Agarwal A.Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate （Viagra）.Urology 1998； 52： 963-6.

206.Feng MI， Huang S， Kaptein J， Kaswick J， Aboseif S.Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction.JUrol 2000； 164： 1935-8.

207.Tal R， Valenzuela R， Aviv N， etal.Persistenterectile dysfunction following radical prostatectomy： the association between nerve-sparing status and the prevalence and chronology of venous leak.J Sex Med 2009；6：2813-9.

208.Tal R， Alphs HH， Krebs P， Nelson CJ， Mulhall JP.Erectile function recovery rate after radical prostatectomy： ameta-analysis.JSex Med 2009； 6： 2538-46.

209.Schwartz EJ， Wong P， Graydon RJ.Sildenafil preserves intracorporeal smoothmuscle after radical retropubic prostatectomy.JUrol 2004； 171： 771-4.

210.Mulhall JP，Parker M，Waters BW，Flanigan R.The timing of penile rehabilitation after bilateral nervesparing radical prostatectomy affects the recovery of erectile function.BJU Int 2010； 105： 37-41.

211.Mosbah A， El Bahnasawy M， Osman Y， Hekal IA， Abou-Beih E， Shaaban A.Early versus late rehabilitation of erectile function after nerve-sparing radical cystoprostatectomy：a prospective randomized study.JSex Med 2011； 8： 2106-11.

212.Canat L， Guner B， Gurbuz C， Atis G， Caskurlu T.Effects of three-times-per-week versus on-demand tadalafil treatment on erectile function and continence recovery following bilateral nerve sparing radical prostatectomy：results of a prospective， randomized， and single-center study.Kaohsiung JMed Sci2015； 31： 90-5.

213.Montorsi F， Brock G， Lee J， et al.Effect of nightly versus on-demand vardenafil on recovery of erectile function inmen following bilateral nerve-sparing radical prostatectomy.Eur Urol 2008； 54： 924-31.

214.Moncada I， de Bethencourt FR， Lledo-Garcia E， et al.Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy. World JUrol 2015； 33： 1031-8.

215.Salonia A，Burnett AL，Graefen M，et al.Prevention and management of postprostatectomy sexual dysfunctions part 2： recovery and preservation of erectile function， sexual desire， and orgasmic function.Eur Urol 2012； 62： 273-86.

216.Montorsi F，McCullough A.Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy： a systematic review of clinical data.JSex Med 2005； 2： 658-67.

217.Montorsi F，Nathan HP， McCullough A，etal.Tadalafil in the treatmentof erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy： a randomized， double-blind， placebo controlled trial. JUrol 2004； 172： 1036-41.

218.Montorsi F，Brock G，Stolzenburg JU，et al.Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy： a randomised placebo-controlled study（REACTT）.Eur Urol 2014； 65： 587-96.

219.Welliver RC， Jr.， Mechlin C， Goodwin B， Alukal JP， McCullough AR.A pilot study to determine penile oxygen saturation before and after vacuum therapy in patientswith erectile dysfunction after radical prostatectomy.JSex Med 2014； 11： 1071-7.

220.Raina R，Agarwal A， Ausmundson S，et al.Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function.Int J Impot Res 2006； 18： 77-81.

221.Dalkin BL， Christopher BA.Preservation of penile length after radical prostatectomy： early intervention with a vacuum erection device.Int J Impot Res 2007； 19： 501-4.

222.Nandipati K， Raina R， Agarwal A， Zippe CD.Early combination therapy： intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections.Int J Impot Res 2006； 18： 446-51.

223.卞惠娟.性行为指导对中青年男性直肠癌Miles术后性功能的影响.现代中西医结合杂志 2015：672-4.

224.阮衍泰，郜亮，曾汉东.高泌乳素血症对男性性功能障碍和不育的影响与治疗探讨.中国男科学杂志2013：59-63.

225.白文俊，王晓峰，李荣强等.高泌乳素血症导致男性性功能障碍的诊断与治疗.中华泌尿外科杂志2007； 28： 424-6.

226.朱禧星、胡仁明.内分泌代谢疾病诊治策略.上海科学技术出版社2009.

227.李延兵、梁柳琴.内分泌及风湿病临床诊断与治疗方案.科学技术文献出版社2011.

228.高催乳素血症诊疗共识.（中华医学会神经外科学分会，中华医学会妇产科学分会，中华医学会内分泌学分会）.中华医学杂志2011；91：147-54.

229.《高催乳素血症诊疗共识》编写组.高催乳素血症诊疗共识.中华妇产科杂志2009；44：712-8.

230.Melmed S， Casanueva FF， Hoffman AR， et al.Diagnosis and treatment of hyperprolactinemia： an Endocrine Society clinical practice guideline.JClin Endocrinol Metab 2011； 96： 273-88.

231.Serri O， Chik CL， Ur E， Ezzat S.Diagnosis and management of hyperprolactinem ia.Cmaj 2003； 169：575-81.

232.邓春华，张亚东，陈鑫.重视轻症勃起功能障碍的诊治.中华男科学杂志2015；21：6-10.

233.王陇德.慢性病及亚健康状态对我国人民健康的影响及其防治原则.中华医学杂志 2003；83：1031-4.

234.Sand MS， FisherW， Rosen R， Heiman J， Eardley I.Erectile dysfunction and constructsofmasculinity and quality of life in themultinational Men＇s Attitudes to Life Events and Sexuality （MALES） study.JSex Med 2008； 5： 583-94.

235.Gupta BP， Murad MH， Clifton MM， Prokop L， Nehra A， Kopecky SL.The effectof lifestylemodification and cardiovascular risk factor reduction on erectile dysfunction：a systematic review and meta-analysis.Arch Intern Med 2011； 171： 1797-803.

236.Kupelian V，Araujo AB，Chiu GR，Rosen RC，McKinlay JB.Relative contributions ofmodifiable risk factors to erectile dysfunction： results from the Boston Area Community Health （BACH） Survey.Prev Med 2010； 50： 19-25.

237.Bacon CG， Mittleman MA， Kawachi I， Giovannucci E， Glasser DB， Rimm EB.A prospective study of risk factors for erectile dysfunction.JUrol 2006； 176： 217-21.

238.Esposito K， Giugliano F， Di Palo C， et al.Effect of lifestyle changes on erectile dysfunction in obesemen：a random ized controlled trial.Jama 2004； 291： 2978-84.

239.Hannan JL， Maio MT， Komolova M， Adams MA.Beneficial impact of exercise and obesity interventions on erectile function and its risk factors.JSex Med 2009； 3： 254-61.

240.Widmer RJ， Flammer AJ， Lerman LO， Lerman A.The Mediterranean diet， its components， and cardiovascular disease.Am JMed 2015； 128： 229-38.

241.Cassidy A，Franz M，Rimm EB.Dietary flavonoid intake and incidence of erectile dysfunction.Am JClin Nutr 2016； 103： 534-41.

242.Qin Z， Tian B， Wang X， Liu T， Bai J.Impactof frequency of intercourse on erectile dysfunction： a crosssectional study in Wuhan， China.JHuazhong Univ Sci Technolog Med Sci2012； 32： 396-9.

243.Miner M， Nehra A， Jackson　G， et al.All men　with　vasculogenic erectile dysfunction　require a cardiovascular workup.Am JMed 2014； 127： 174-82.

244.Chen S， Wu R， Huang Y， et al.Insulin resistance is an independent determinate of ED in young adult men.PLoSOne 2013；8.

245.Yao F， Huang Y， Zhang Y， et al.Subclinical endothelial dysfunction and low-grade inflammation p lay roles in the development of erectile dysfunction in youngmen with low risk of coronary heart disease.Int JAndrol 2012； 35： 653-9.

246.Huang Y， Sun X， Liu G， et al.Glycosylated Serum Protein May Improve Our Ability to Predict Endothelial and Erectile Dysfunction in Nonorganic Patients.The Journal of SexualMedicine 2011； 8： 840-50.

247.Nehra A，Jackson G，Miner M，etal.The PrincetonⅢConsensus recommendations for themanagementof erectile dysfunction and cardiovascular disease.Mayo Clin Proc 2012； 87： 766-78.

248.Walz J， Epstein JI， Ganzer R， et al.A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy： An Update.Eur Urol 2016； 2： 128-7.

249.Recabal P， Assel M， Musser JE， et al.Erectile Function Recovery after Radical Prostatectomy in Men with High Risk Features.JUrol 2016； 22： 080.

250.Mulhall JP，Brock G，Oelke M，et al.Effects of Tadalafil Once-Daily or On-Demand vs Placebo on Return to Baseline Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy-Results from a Randomized Controlled Trial（REACTT）.JSex Med 2016； 13： 679-83.

251.Montorsi F， Oelke M， Henneges C， et al.Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy.Eur Urol 2016； 3： 214-1.